Citrine Medicine To Current at the 2021 WuXi Healthcare Discussion board and Take part in Two More Forthcoming Health care Conferences

Tom Smith

CAMBRIDGE, Mass. and SHANGHAI, March 16, 2021 /PRNewswire/ — Citrine Medication, a China-based mostly rare condition therapeutics organization, these days declared that it will participate in a few industry conferences in March, together with a presentation at the 2021 WuXi Health care Discussion board, which will be held from March […]

CAMBRIDGE, Mass. and SHANGHAI, March 16, 2021 /PRNewswire/ — Citrine Medication, a China-based mostly rare condition therapeutics organization, these days declared that it will participate in a few industry conferences in March, together with a presentation at the 2021 WuXi Health care Discussion board, which will be held from March 15-18, 2021.

(PRNewsfoto/Citrine Medicine)

Convention specifics are as follows:

  • WuXi Healthcare Discussion board: Citrine’s administration will take part in the CEO Roundtable on March 16 from 6:15-6:45 p.m. PT, and on March 17 from 6:45-7:15 p.m. PT. The discussion will be available dwell and interactively by using a devoted portal for registered attendees.

  • ENDO 2021: Associates of Citrine’s management staff will go to the Endocrine’s Culture Annual Meeting from March 20-23.

  • BIO Europe: Members of Citrine’s administration group will show up at BIO Europe from March 22-25.

About Citrine Drugs

Citrine Drugs is dedicated to increasing the lives of clients with unusual and intractable disorders by building prognosis and necessary treatment options out there and obtainable to all those who require them in China. Our mission is to make the very first scarce ailment ecosystem in China and in executing so, permit people today with unusual illnesses to are living extra ordinary life. In addition to acquiring and promoting exceptional condition medicines, Citrine aims to create a client-centric system which educates people today on exceptional ailments, trains physicians on prognosis and procedure, and assists medical professionals build a total condition management protocol. Citrine’s guide product applicant, Wakix® (pitolisant), is an investigational oral drug in development for the treatment of narcolepsy and obstructive sleep apnea in China. Citrine has initiated an Investigational New Drug (IND) submission for pitolisant in the treatment of narcolepsy and expects to entire the IND submission in the initially quarter of 2021. Citrine also lately introduced a strategic partnership that will let the organization exceptional rights to produce, sign-up, and commercialize Alkindi®—the initially clinically validated pediatric treatment method for congenital adrenal hyperplasia—in the Greater China industry. Citrine is headquartered in Shanghai and has other places of work in Beijing, China and Cambridge, Mass.

For extra facts, take a look at www.citrinemed.com

Citrine Medication Media Contacts:

Sarah Sutton
Finsbury Glover Herring
[email protected]
202-337-0808

Cision

Cision

Look at initial articles to download multimedia:http://www.prnewswire.com/news-releases/citrine-drugs-to-current-at-the-2021-wuxi-health care-discussion board-and-take part-in-two-extra-impending-health care-conferences-301248224.html

Source Citrine Drugs

Next Post

Tequila regulatory body stresses the importance of respecting Geographical Indications of origin - Drinks Intercontinental

By Fernando Cano Treviño, European representative for the Consejo Regulador del Tequila Imagining that they are encountering the authentic style of Tequila, the shopper is transported hundreds of miles from their property in Germany, or France, or the Uk – all the way to the agave fields of Mexico. It’s […]

Subscribe US Now